Hilary Longhurst

Summary

Affiliation: Barts and The London NHS Trust
Country: UK

Publications

  1. ncbi Rhucin, a recombinant C1 inhibitor for the treatment of hereditary angioedema and cerebral ischemia
    Hilary Longhurst
    Barts and The London NHS Trust, Department of Immunology, 80 Newark Street, London E1 2ES, UK
    Curr Opin Investig Drugs 9:310-23. 2008
  2. ncbi Clinical Immunology Review Series: An approach to the patient with angio-oedema
    S Grigoriadou
    Barts and The London NHS Trust, Royal London Hospital, London, UK
    Clin Exp Immunol 155:367-77. 2009
  3. ncbi Hereditary angio-oedema
    Hilary Longhurst
    Department of Immunology, Barts and The London National Health Service Trust, Whitechapel, London, UK
    Lancet 379:474-81. 2012
  4. ncbi 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema
    Tom Bowen
    Departments of Medicine and Paediatrics, University of Calgary, Calgary, Alberta, Canada
    Allergy Asthma Clin Immunol 6:24. 2010
  5. ncbi Management of acute attacks of hereditary angioedema: potential role of icatibant
    Hilary J Longhurst
    Department of Immunology, Barts and The London NHS Trust, London, UK
    Vasc Health Risk Manag 6:795-802. 2010
  6. ncbi HAE international home therapy consensus document
    Hilary J Longhurst
    Department of Immunology, Barts and The London NHS Trust, London, UK
    Allergy Asthma Clin Immunol 6:22. 2010
  7. ncbi C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option
    H J Longhurst
    Barts and The London NHS Trust, Department of Immunopathology, London, UK
    Clin Exp Immunol 147:11-7. 2007
  8. ncbi Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence?
    H J Longhurst
    Department of Immunology, Barts and The London NHS Trust, London, UK
    Int J Clin Pract 59:594-9. 2005
  9. ncbi An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angio-oedema
    M D Tarzi
    Department of Immunopathology, St Barts and the London NHS Trust, London, UK
    Clin Exp Immunol 149:513-6. 2007
  10. ncbi Serological markers (anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic antibodies) in inflammatory bowel disease: diagnostic utility and phenotypic correlation
    M S Buckland
    Department of Clinical Immunology, 1st Floor, 51 53 Barts Close, W Smithfield, St Bartholomew s, London EC1A 7BE, United Kingdom
    Clin Diagn Lab Immunol 12:1328-30. 2005

Collaborators

Detail Information

Publications11

  1. ncbi Rhucin, a recombinant C1 inhibitor for the treatment of hereditary angioedema and cerebral ischemia
    Hilary Longhurst
    Barts and The London NHS Trust, Department of Immunology, 80 Newark Street, London E1 2ES, UK
    Curr Opin Investig Drugs 9:310-23. 2008
    ..Pharming is also investigating Rhucin for the potential treatment of cerebral ischemic injury...
  2. ncbi Clinical Immunology Review Series: An approach to the patient with angio-oedema
    S Grigoriadou
    Barts and The London NHS Trust, Royal London Hospital, London, UK
    Clin Exp Immunol 155:367-77. 2009
    ..A comprehensive history and close monitoring of response to treatment are the most cost-effective diagnostic and treatment tools...
  3. ncbi Hereditary angio-oedema
    Hilary Longhurst
    Department of Immunology, Barts and The London National Health Service Trust, Whitechapel, London, UK
    Lancet 379:474-81. 2012
    ..In this Seminar we review the clinical features, diagnosis, and management of hereditary angio-oedema, with specific emphasis on the new treatments available for acute swellings...
  4. ncbi 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema
    Tom Bowen
    Departments of Medicine and Paediatrics, University of Calgary, Calgary, Alberta, Canada
    Allergy Asthma Clin Immunol 6:24. 2010
    ....
  5. ncbi Management of acute attacks of hereditary angioedema: potential role of icatibant
    Hilary J Longhurst
    Department of Immunology, Barts and The London NHS Trust, London, UK
    Vasc Health Risk Manag 6:795-802. 2010
    ..Its subcutaneous route of administration, good tolerability and novel mode of action make icatibant a promising addition to the limited repertoire of treatments for hereditary angioedema...
  6. ncbi HAE international home therapy consensus document
    Hilary J Longhurst
    Department of Immunology, Barts and The London NHS Trust, London, UK
    Allergy Asthma Clin Immunol 6:22. 2010
    ..It represents the opinion of the authors who have a wide range of expert experience in the management of HAE...
  7. ncbi C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option
    H J Longhurst
    Barts and The London NHS Trust, Department of Immunopathology, London, UK
    Clin Exp Immunol 147:11-7. 2007
    ..Home therapy programmes for HAE are currently being established. This paper reviews the extent of use of these programmes and summarizes the advantages and potential disadvantages of the concept so far...
  8. ncbi Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence?
    H J Longhurst
    Department of Immunology, Barts and The London NHS Trust, London, UK
    Int J Clin Pract 59:594-9. 2005
    ..It is concluded that while all three treatment options are theoretically effective in the emergency treatment of HAE, C1-INH is the treatment of choice...
  9. ncbi An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angio-oedema
    M D Tarzi
    Department of Immunopathology, St Barts and the London NHS Trust, London, UK
    Clin Exp Immunol 149:513-6. 2007
    ..The diagnosis of HAE is not excluded by normal levels of complement C4. We conclude that C1 inhibitor studies should be performed regardless of serum C4 where a high index of clinical suspicion exists...
  10. ncbi Serological markers (anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic antibodies) in inflammatory bowel disease: diagnostic utility and phenotypic correlation
    M S Buckland
    Department of Clinical Immunology, 1st Floor, 51 53 Barts Close, W Smithfield, St Bartholomew s, London EC1A 7BE, United Kingdom
    Clin Diagn Lab Immunol 12:1328-30. 2005
    ..Sensitivity, specificity, and phenotypic correlations were investigated. The implications of our findings for implementing these tests in routine clinical testing are discussed...
  11. ncbi Helicobacter pylori infection as a triggering factor of attacks in patients with hereditary angioedema
    Beata Visy
    Madarász Street Hospital of the Heim Pál Pediatric Hospital, Budapest, Hungary
    Helicobacter 12:251-7. 2007
    ..The present study aimed to reinvestigate the relationship between H. pylori infection and the attack rate in the framework of an international collaborative study...